Introduction
============

Pancreatic cancer remains a leading cause of cancer deaths in the advanced nation ([@b1-ijo-42-02-0403],[@b2-ijo-42-02-0403]). The overall 5-year survival rate is reported to be less than 5% ([@b3-ijo-42-02-0403]). A reliable and clinically relevant prognostic biomarker which can stratify the disease is needed for developing new strategies.

It is a known fact that chromatin, highly condensed and dynamically structured, can be temporally rearranged so that specific genes can be expressed or repressed ([@b4-ijo-42-02-0403]). Studies have shown that modification of chromatin structure is an essential step in gene regulation primarily mediated by chromatin remodeling proteins. Among these proteins, histone is known to play a dynamic role in the regulation of transcription ([@b5-ijo-42-02-0403]--[@b7-ijo-42-02-0403]). Often, transcription is also regulated by other cofactors, and the balance of chromatin remodeling activities may be crucial to ensure accurate responses to developmental or environmental cues and to prevent the transition of normal cells into cancer cells ([@b8-ijo-42-02-0403]).

The SWItch/sucrose non-fermentable (SWI/SNF) complex is a major complex of adenosine triphosphate (ATP)-dependent chromatin remodeling factors and controls the transcriptional activity of a variety of genes involved in cellular growth and transformation by altering chromatin structure ([@b9-ijo-42-02-0403]--[@b13-ijo-42-02-0403]). SWI/SNF complex, originally identified in yeast, is composed of more than 10 characterized subunits ([@b14-ijo-42-02-0403],[@b15-ijo-42-02-0403]) and human SWI/SNF complexes contain one of the two core ATPase subunits, BRM or BRG1 ([@b13-ijo-42-02-0403],[@b16-ijo-42-02-0403]--[@b18-ijo-42-02-0403]). Growing genetic and molecular evidence indicates that specific subunits of the SWI/SNF complex can act as tumor suppressors ([@b6-ijo-42-02-0403],[@b19-ijo-42-02-0403]). However, there is no report on the relationship between SWI/SNF components expression and the clinical significance of pancreatic cancer. In this study, we investigated the expression levels of SWI/SNF components to clarify the clinical impact of SWI/SNF complex on pancreatic cancer.

Materials and methods
=====================

Patients and samples
--------------------

The surgical specimens of pancreatic cancer tissue obtained from 68 patients were evaluated. All of the patients had undergone macroscopically curative resection (R0, 1) at Kanagawa Cancer Center between July 2006 and April 2010. The clinicopathological characteristics of these patients are shown in [Table I](#t1-ijo-42-02-0403){ref-type="table"}. In all cases, archival hematoxylin and eosin-stained (H&E) slides of the primary tumor were retrieved and reviewed to confirm the pathological features as well as to select suitable tissue blocks for immunohistochemical analysis. Informed consent was obtained from each patient. The Ethics Committees of the Kanagawa Cancer Center approved the protocol before initiation of the study. We declare no conflicts of interest.

Tissue microarrays and immunohistochemistry
-------------------------------------------

Microarrays consisting of cores, each measuring 2 mm in diameter, were prepared from formalin-fixed paraffin-embedded tissue blocks of surgically removed primary tumors. Each tissue core of the primary tumor was sampled.

Immunohistochemical staining was performed using commercially available polyclonal rabbit, or mouse antibodies raised against BRM (Abcam Inc., Cambridge, MA), BRG1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), BAF250a (Santa Cruz Biotechnology Inc.), BAF180 (Sigma-Aldrich Inc., St. Louis, MO), BAF47 (Santa Cruz Biotechnology Inc.). Tissue microarray blocks were sectioned at a thickness of 4 *μ*m and mounted on pre-coated glass slides. The sections were de-paraffinized through a graded series of xylene and rehydrated through a graded series of alcohol to distilled water. Endogenous peroxidase was quenched with 3% hydrogen peroxide in methanol at room temperature. The sections were placed in a 95°C solution of 0.01 M sodium citrate buffer (pH 6.0) for 40 min for antigen retrieval. Normal goat serum (5%) was then applied for 15 min to block any non-specific protein binding sites. Primary polyclonal antibodies were applied for 1 h at room temperature at the following dilutions: anti-BRM at 1:250, anti-BRG1 at 1:200, anti-BAF250a at 1:100, anti-BAF180 at 1:90 and BAF47 at 1:300. Immunoreactive proteins were detected using the Simple Stain MAX-PO (Multi).

All sections were counterstained with Mayer's hematoxylin, and negative controls were included in each staining sequence. The intensity and global level of staining were scored semi-quantitatively for each tissue microarray by an investigator blinded to all of the clinicopathological variables. The global level of staining refers to the percentage of tumor cells that stained positively for an antibody within each tissue microarray at ×200 magnification using a light microscope.

Scoring of immunohistochemical reactivity
-----------------------------------------

Immunohistochemical scoring was completed using the modified Histoscore (H-score) ([@b20-ijo-42-02-0403]), which involves a semiquantitative assessment of both the intensity of staining (graded as: 0, non-staining; 1, weak; 2, median; or 3, strong using adjacent normal mucosa as the median) and the percentage of positive cells ([Fig. 1](#f1-ijo-42-02-0403){ref-type="fig"}). The range of possible scores was from 0 to 300. Expression level of each component was categorized as low or high according to the median value of H-score.

Statistical analysis
--------------------

The relationships between the expression level and the clinicopathological factors were evaluated with the χ^2^ test. The postoperative survival rate from the day of primary tumor resection was analyzed using the Kaplan-Meier method and any differences in the survival rates were assessed with the log-rank test. A Cox proportional-hazard model was used for the multivariate analyses. Differences were considered significant when P\<0.05. The statistical analysis was performed using the PASW Statistics 18 (SPSS, Inc., Chicago, IL).

Results
=======

Relation of SWI/SNF component expression to clinicopathological features
------------------------------------------------------------------------

The distribution of H-score is showed in [Fig. 2](#f2-ijo-42-02-0403){ref-type="fig"}. Expression level of the SWI/SNF components was categorized as low or high according to the median value of the H-score. Relations between the expression levels of each component and clinicopathological features were then examined. Factors implicating significant relations were tumor size, T factor, M factor, lymphatic invasion, and stage in BRM, histology and stage in BRG1, tumor size in BAF180, lymphatic invasion in BAF47, respectively ([Table II](#t2-ijo-42-02-0403){ref-type="table"}).

Analysis of prognostic factors in all patients
----------------------------------------------

Univariate Cox regression analysis for overall survival in all patients showed that age, tumor size, histological type, M factor, curability of the surgery, and expression level of BRM as well as BAF180 were significant predictors ([Table III](#t3-ijo-42-02-0403){ref-type="table"}). On multivariate Cox proportional hazard analysis, histology, expression level of BRM and BAF180 were significant independent predictors of overall survival in patients with pancreatic cancer ([Table IV](#t4-ijo-42-02-0403){ref-type="table"}).

Comparison of survival by the status of BRM and BAF180
------------------------------------------------------

The 5-year survival rate of high BRM patients was 9.8%, which was significantly worse than that of low BRM patients (43.8%) ([Fig. 3](#f3-ijo-42-02-0403){ref-type="fig"}). Also, the 5-year survival rate of low BAF180 (8.1%) was significantly worse than that of high BAF180 patients (40.8%) ([Fig. 3](#f3-ijo-42-02-0403){ref-type="fig"}).

Hazard analysis of SWI/SNF components in the patients treated with adjuvant gemcitabine
---------------------------------------------------------------------------------------

Multivariate analysis ([Table V](#t5-ijo-42-02-0403){ref-type="table"}) and survival analysis ([Fig. 4](#f4-ijo-42-02-0403){ref-type="fig"}) showed that BRM-high and BAF180-low were independent prognostic factors for overall survival in the patients treated with adjuvant gemcitabine.

Discussion
==========

Chromatin remodeling factors have been the subject of great interest in oncology. However, little is known about their role in pancreatic cancer.

The SWI/SNF complexes are large, multi-subunit complexes containing 10 or more subunits, serving as a master switch that directs and limits the execution of specific cellular programs, such as differentiation and growth control ([@b21-ijo-42-02-0403]). Each complex has one of the two different ATPase as core motor; BRM or BRG1, and subunits which are referred to as BAFs (BRM- or BRG1-associated factors). The BRM-containing complex is termed BRM/BAF. The BRG1-containing complexes are further divided into those that contain the BAF250a (termed BRG1/BAF) or the BAF180 (termed PBAF). These three types of complexes are believed to have different molecular functions ([@b22-ijo-42-02-0403]).

There are several studies reporting that the subunit of SWI/SNF complex was decreased in cancer tissues. They revealed the mutation of *ARID1A*, which codes BAF250a protein, in about half of ovarian clear cell carcinomas ([@b23-ijo-42-02-0403],[@b24-ijo-42-02-0403]), and *PBRM1*, which codes BAF180, in approximately 40% of renal cell carcinomas ([@b25-ijo-42-02-0403]). Another study identified the SWI/SNF chromatin remodeling complex as tumor suppressor, by mediating retinoblastoma protein (RB)-derived regulation of the cell cycle ([@b22-ijo-42-02-0403],[@b26-ijo-42-02-0403],[@b27-ijo-42-02-0403]). However, the roles of these subunits in pancreatic cancers are poorly understood.

In this study, we investigated the expression levels of 5 key subunits; BRM, BRG1, BAF250a, BAF180, which are the key subunits when subdividing complex types, and BAF47. There is established evidence that BAF47 is a tumor suppressor in rhabdoid tumors ([@b28-ijo-42-02-0403]).

In the analysis of expression level and clinicopahological features, high BRM was related to worse clinicopathological features in general, including larger tumor size, T4 disease, other organ metastasis, lymphatic invasion, and stage IV disease. Stage IV disease was also correlated to high BRG1, which is reported to have similar biological function as BRM. On the other hand, better clinicopathological features were related to high BAF expression. High BAF180 was related to smaller tumor size, and high BAF47 was associated with negative lymphatic invasion.

In addition, our multivariate analysis revealed both high BRM and low BAF180 were independent prognostic indicators for poor survival, whereas the expression level of BRG1, BAF250a, and BAF47 were not related to overall survival.

As a next step, we investigated the prognostic significance of these factors in the patients with adjuvant gemcitabine. Gemcitabine remains standard therapy in the adjuvant and palliative settings for pancreatic cancer ([@b29-ijo-42-02-0403],[@b30-ijo-42-02-0403]). However, the response rate of gemcitabine is very low, with only 18% of 1-year survival rate ([@b31-ijo-42-02-0403]). Developing a novel biomarker, which predicts the response for gemcitabine, is urgently needed. In the analysis of the patients with gemcitabine, we reached the same result; both high BRM and low BAF180 were independent prognostic indicators for poor survival.

A previous study showed that BRM or BRG1 is lost in 10--20% of the bladder, colon, breast, esophageal, pancreatic and ovarian cancers by immunohistochemical staining of tissue microarrays ([@b32-ijo-42-02-0403]). Another study reported BRM was lost in approximately 15--20% of primary non-small lung cancers, and silencing of BRM was a prognostic factor for poor outcome ([@b33-ijo-42-02-0403],[@b34-ijo-42-02-0403]). Although BRM is supposed to be involved in many biological functions, these data showed BRM-containing complexes (BRM/BAF) as tumor suppressor in cancer tissue.

It is also reported that BRM has a role in trans cription of CD44 ([@b35-ijo-42-02-0403]), which is important in the process of tumor-endothelium interactions, cell migration, cell adhesion, tumor progression and metastasis ([@b36-ijo-42-02-0403]).

Our result showed that the patient with high BRM had a significantly worse survival than those without (5-year OS: 9.8 vs. 43.8%, p=0.009), suggesting BRM/BAF in pancreatic cancer may contribute to tumor progression.

We also revealed the significant relationship between high BAF180 expression and smaller-sized tumor, and identified BAF180 as an independent prognostic factor for better survival in pancreatic cancer.

BAF180 maps to the 3p12 region ([@b37-ijo-42-02-0403]) where allele loss is frequent and homozygous deletion have been detected in lung and breast cancer cell lines ([@b38-ijo-42-02-0403],[@b39-ijo-42-02-0403]). Thus, genes located on this region have been thought as candidates for tumor suppressors. Actually, it is reported that BAF180 mutation is associated with carcinogenesis of breast cancer, and BAF180 suppresses tumorigenesis through its ability to regulate p21 ([@b40-ijo-42-02-0403]), which controls the cell cycle ([@b41-ijo-42-02-0403]). Recent research also clarified BAF180 mutation in clear cell renal cell carcinoma ([@b42-ijo-42-02-0403]). These results suggest the idea that BAF180-containing complexes (PBAF) suppress tumor progression, which does not contradict our present results.

BAF250a-containing SWI/SNF complexes (BRG1/BAF) are reported to have different structure and biological properties from PBAF ([@b43-ijo-42-02-0403],[@b44-ijo-42-02-0403]). A previous study showed that BAF250a was deleted in as many as 30% of renal cell carcinoma and 10% of breast carcinoma ([@b19-ijo-42-02-0403],[@b45-ijo-42-02-0403]). These results lead to the concept that BRG1/BAF appear to have antagonistic effect on cell cycle progression ([@b46-ijo-42-02-0403]). However, our data did not show the relationship of BAF250a expression to clinicopathological features or overall survival in pancreatic cancer.

Based on this study, we reached the conclusion that high BRM, and low BAF180 are useful biomarker not only for the patients with curative resection, but also for those with adjuvant gemcitabine. Future investigation into biological functions of SWI/SNF components could lead to better management in pancreatic cancer.

![Histoscore (H-score) was calculated by a semi-quantitative assessment of both the intensity of staining (graded as: 0, non-staining; 1, weak; 2, median; or 3, strong using adjacent normal mucosa as the median) and the percentage of positive cells. The range of possible scores was from 0 to 300. Expression level of each component was categorized as low or high according to the median value of the H-score.](IJO-42-02-0403-g00){#f1-ijo-42-02-0403}

![The distribution of the H-score is shown in the box plot. The horizontal bar shows the median value of each score.](IJO-42-02-0403-g01){#f2-ijo-42-02-0403}

![The survival curves were compared by Kaplan-Maier method by the expression level of BRM and BAF180. The statistical significance was evaluated using log-rank test.](IJO-42-02-0403-g02){#f3-ijo-42-02-0403}

![The survival curves of patients with adjuvant gemcitabine were compared by Kaplan-Maier method by the expression level of BRM and BAF180. The statistical significance was evaluated using log-rank test.](IJO-42-02-0403-g03){#f4-ijo-42-02-0403}

###### 

The clinicopathological characteristics of all patients.

  Clinicopathological characteristics   No. of patients (n=68)
  ------------------------------------- ------------------------
  Age                                   
    \<65                                30
    ≥65                                 38
  Sex                                   
    Male                                36
    Female                              32
  Tumor location in pancreas            
    Head                                46
    Body/tail                           22
  Tumor size (cm)                       
    \<4                                 29
    ≥4                                  39
  Histological type                     
    Well/mod                            32
    Poor                                36
  T                                     
    T1--3                               38
    T4                                  30
  N                                     
    N0                                  17
    N1                                  51
  M                                     
    M0                                  53
    M1                                  15
  Curability of surgery                 
    R0                                  43
    R1                                  25
  Stage                                 
    0--III                              53
    IV                                  15
  Adjuvant gemcitabine                  
    Yes                                 42
    No                                  26

Well, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma.

###### 

Relation of SWI/SNF component expression to clinicopathological factors.

                       BRM     BRG1    BAF250a   BAF180   BAF47                                                                           
  -------------------- ------- ------- --------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Age (years)                                                                                                                             
    \<65/≥65           15/19   15/19   1.000     18/19    12/22   0.143   13/21   17/17   0.329   19/15   11/23   0.051   13/21   17/17   0.329
  Gender                                                                                                                                  
    Male/female        16/18   16/18   1.000     16/18    16/18   1.000   13/21   19/15   0.145   15/19   17/17   0.627   17/17   15/19   0.627
  Tumor size                                                                                                                              
    \<4/≥4 cm          19/15   10/24   0.027     12/22    17/17   0.220   14/20   15/19   0.806   10/24   19/15   0.027   15/19   14/20   0.806
  Histology                                                                                                                               
    Well, mod/poor     18/16   14/20   0.331     11/23    21/13   0.015   14/20   18/16   0.331   13/21   19/15   0.145   15/19   17/17   0.627
  T                                                                                                                                       
    T1-3/4             25/9    13/21   0.003     23/11    15/19   0.051   17/17   21/13   0.329   19/15   19/15   1.000   20/14   18/16   0.625
  N                                                                                                                                       
    N0/N1              9/25    8/26    0.779     10/24    7/27    0.401   10/24   7/27    0.401   8/26    9/25    0.779   9/25    8/26    0.779
  M                                                                                                                                       
    M0/M1              30/4    23/11   0.041     27/7     26/8    0.770   24/10   29/5    0.114   25/9    28/6    0.380   28/6    25/9    0.380
  Vessel invasion                                                                                                                         
    No/yes             12/22   8/26    0.287     11/23    9/25    0.595   7/27    13/21   0.110   10/24   10/24   1.000   8/26    12/22   0.287
  Lymphatic invasion                                                                                                                      
    No/yes             15/19   6/28    0.018     13/21    8/26    0.189   9/25    12/22   0.431   9/25    12/22   0.431   15/19   6/28    0.018
  Stage                                                                                                                                   
    0--III/IV          18/16   5/29    0.001     17/17    6/28    0.005   10/24   13/21   0.442   11/23   12/22   0.798   14/20   9/25    0.200
  Curability                                                                                                                              
    R0/R1              25/9    18/16   0.078     23/11    20/14   0.451   20/14   23/11   0.451   21/13   22/12   0.801   20/14   23/11   0.451

Well, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma; inv, invasion.

###### 

Univariate analysis for overall survival in pancreatic cancer.

  Factors                 HR (95% CI)            p-value
  ----------------------- ---------------------- ---------
  Age (years)                                    0.035
    \<65                  1.0                    
    ≥65                   0.533 (0.293--0.967)   
  Sex                                            0.632
    Male                  1.0                    
    Female                0.865 (0.478--1.565)   
  Tumor size (cm)                                0.035
    \<4                   1.0                    
    ≥4                    1.979 (1.048--3.739)   
  Histology                                      0.002
    Well/mod              1.0                    
    Poor                  2.744 (1.429--5.271)   
  T                                              0.071
    T1--3                 1.0                    
    T4                    1.733 (0.955--3.146)   
  N                                              0.602
    N0                    1.0                    
    N1                    1.208 (0.594--2.458)   
  M                                              0.010
    M0                    1.0                    
    M1                    2.329 (1.222--4.439)   
  Curability of surgery                          0.020
    R0                    1.0                    
    R1                    2.068 (1.121--3.815)   
  BRM                                            0.011
    Low                   1.0                    
    High                  2.225 (1.199--4.129)   
  BRG1                                           0.601
    Low                   1.0                    
    High                  0.853 (0.471--1.546)   
  BAF250a                                        0.479
    Low                   1.0                    
    High                  0.807 (0.446--1.461)   
  BAF180                                         0.007
    Low                   1.0                    
    High                  0.428 (0.231--0.793)   
  BAF47                                          0.226
    Low                   1.0                    
    High                  0.690 (0.378--1.258)   

HR, hazard ratio; 95% CI, 95% confidence interval; well, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma.

###### 

Multivariate analysis for overall survival in pancreatic cancer.

  Factors                 HR (95% CI)            p-value
  ----------------------- ---------------------- ---------
  Age                                            0.169
    \<65                  1.0                    
    ≥65                   0.633 (0.330--1.214)   
  Tumor size (cm)                                0.755
    \<4                   1.0                    
    ≥4                    1.122 (0.543--2.318)   
  Histology                                      0.011
    Well/Mod              1.0                    
    Poor                  2.702 (1.253--5.830)   
  M                                              0.486
    M0                    1.0                    
    M1                    1.381 (0.557--3.424)   
  Curability of surgery                          0.076
    R0                    1.0                    
    R1                    1.981 (0.932--4.214)   
  BRM                                            0.032
    Low                   1.0                    
    High                  2.144 (1.066--4.311)   
  BAF180                                         0.041
    Low                   1.0                    
    High                  0.501 (0.258--0.971)   

HR, hazard ratio; 95% CI, 95% confidence interval; well, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma.

###### 

Multivariate analysis for overall survival in patients with adjuvant gemcitabine.

  Factors                 HR (95% CI)            p-value
  ----------------------- ---------------------- ---------
  Age                                            0.002
    \<65                  1.0                    
    ≥65                   0.227 (0.089--0.580)   
  Tumor size (cm)                                0.280
    \<4                   1.0                    
    ≥4                    0.593 (0.230--1.531)   
  Histology                                      0.267
    Well/Mod              1.0                    
    Poor                  1.907 (0.610--5.964)   
  M                                              0.923
    M0                    1.0                    
    M1                    0.947 (0.315--2.847)   
  Curability of surgery                          0.784
    R0                    1.0                    
    R1                    1.145 (0.433--3.029)   
  BRM                                            0.017
    Low                   1.0                    
    High                  3.411 (1.251--9.305)   
  BAF180                                         0.016
    Low                   1.0                    
    High                  0.336 (0.138--0.819)   

HR, hazard ratio; 95% CI, 95% confidence interval; well, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma.
